|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:awarded
|
gptkb:2019_Prix_Galien_USA_Award_for_Best_Biotechnology_Product_(Onpattro)
|
|
gptkbp:CEO
|
gptkb:Yvonne_Greenstreet
|
|
gptkbp:collaboratedWith
|
gptkb:Sanofi
gptkb:Novartis
gptkb:Regeneron_Pharmaceuticals
gptkb:Vir_Biotechnology
|
|
gptkbp:focusesOn
|
RNA interference therapeutics
|
|
gptkbp:foundedYear
|
2002
|
|
gptkbp:founder
|
gptkb:David_Bartel
gptkb:John_Maraganore
gptkb:Paul_Schimmel
gptkb:Phillip_Zamore
gptkb:Thomas_Tuschl
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:notableProduct
|
gptkb:Amvuttra
gptkb:Givlaari
gptkb:Onpattro
gptkb:Oxlumo
|
|
gptkbp:numberOfEmployees
|
over 1,400
|
|
gptkbp:patent
|
RNAi therapeutics
|
|
gptkbp:publiclyTraded
|
yes
|
|
gptkbp:researchInterest
|
cardiometabolic diseases
central nervous system diseases
hepatic infectious diseases
rare genetic diseases
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:_ALNY
|
|
gptkbp:website
|
https://www.alnylam.com/
|
|
gptkbp:bfsParent
|
gptkb:Phillip_Sharp
gptkb:Phillip_A._Sharp
gptkb:Amy_Schulman
|
|
gptkbp:bfsLayer
|
5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Alnylam Pharmaceuticals
|